Supplemental material
Hematology
Volume 24, 2019 - Issue 1
Articles
A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemiaFootnote11 Supplemental data for this article can be accessed https://doi.org/10.1080/16078454.2019.1631425.
, , 
, &
Patompong UngprasertClinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailandhttps://orcid.org/0000-0002-4817-9404
https://orcid.org/0000-0002-4817-9404, & Weerapat OwattanapanichDivision of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandCorrespondence[email protected]
https://orcid.org/0000-0002-1262-2005
https://orcid.org/0000-0002-1262-2005Related Research Data
Predictive prognostic models for outcome
Source:
Wiley
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
Source:
Springer Nature
Older Patients With Acute Myeloid Leukemia Benefit From Intensive Chemotherapy: An Update From the Swedish Acute Leukemia Registry
Source:
Elsevier BV
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
Source:
Ferrata Storti Foundation (Haematologica)
Improved Survival of Elderly-fit Patients With Acute Myeloid Leukemia Requiring Intensive Therapy: 3-Year Multicenter Analysis From TALWG
Source:
Elsevier BV
Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia
Source:
Ovid Technologies (Wolters Kluwer Health)
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
Source:
Massachusetts Medical Society
Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
Source:
MDPI AG
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
Source:
Informa UK Limited
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Source:
American Society of Hematology
Interest of the association azacitidine–lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype
Source:
Springer Nature
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
Source:
Springer Science and Business Media LLC
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
Source:
American Society of Hematology
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)—ViLen-01 protocol
Source:
Springer Nature
Measuring inconsistency in meta-analyses
Source:
BMJ
A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.
Source:
Springer Science and Business Media LLC
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Source:
American Society of Clinical Oncology (ASCO)
Linking provided by
